BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$67.94+1.55 (+2.33%)
Close on Oct 19, 2026
- Market cap
- $13.30B
- P/E (TTM)
- –
- Dividend yield
- –
BridgeBio Pharma, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q4 24 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | $657.16M | $506.23M | $362.37M | $219.24M | $111.12M | $2.88M | – | $1.55M | $3.51M | $4.27M | $5.25M | $3.79M | 92.2% | +491.4% |
| Royalty revenue | $34.49M | $20.68M | $11.39M | $6.28M | $2.00M | $169.00K | – | – | – | – | – | – | 4.8% | +1627.1% |
| License and services revenue | $21.42M | $53.05M | $128.32M | $128.27M | $122.69M | $218.85M | $77.69M | $76.09M | $85.16M | $86.41M | $65.70M | $65.92M | 3.0% | -82.5% |
| License | – | – | – | – | – | – | – | – | – | – | $65.70M | $65.92M | – | – |
By region
From the segment and revenue-disaggregation notes of BridgeBio Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.